"All of these drug classes
have medications that are available generically. In general, the choice of
treatment of Parkinson's disease depends on the patient and their disease
state. Each drug has its trade-off."
— April Kunze,
Pharm.D., senior director, clinical formulary development and trend management
strategy at Prime Therapeutics LLC, spoke with AIS's RADAR on Drug Benefits
about whether payers are picking up coverage of the three new Parkinson's
disease therapies the FDA approved over the past year.
No comments:
Post a Comment